Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The study will evaluate the efficacy and safety of BM32 in grass pollen allergic subjects. It will test the hypothesis that either of two doses of BM32 will lead to a sustained relief off allergy symptoms over a two year study period.
Epistemonikos ID: 92fe9ecdb5e14508be58d3ff321894d3f0a3e4ad
First added on: May 10, 2024